Search results for "LOD"

Sievietes tēls un viņas emociju atainojums Su Tun romānā “Sievas un konkubīnes”

2018

Su Tun ir uzskatāms par vienu no Ķīnas izcilākajiem mūsdienu 20. gadsimta otrās puses rakstniekiem. Viņš ir piecu romānu un 14 īso stāstu autors. Darbi ir publicēti Ķīnas Tautas Republikā, Taivānā, ASV, Francijā, Itālijā un citās valstīs. Daudzi viņa darbi tika ekranizēti. Viņa literatūra aizrauj lasītāju ar savām detaļām un tēliem, kas paliek lasītāja prātā, liekot viņam domāt un pārdzīvot par varoņiem un viņu dzīvi. Maģistra darba tēma ir “Sievietes tēls un viņas emociju atainojums Su Tun romānā „Sievas un konkubīnes””. Darba mērķis bija veikt romāna „Sievas un konkubīnes” analīzi un atrast tā specifiskās iezīmes, lai iezīmētu sieviešu tēlus un lai noskaidrotu, kā autors Su Tun ar valodu,…

Patterning of Magnetic Bimetallic Coordination Nanoparticles of Prussian Blue Derivatives by the Langmuir–Blodgett Technique

2012

We report a novel method to prepare patterns of nanoparticles over large areas of the substrate. This method is based on the adsorption of the negatively charged nanoparticles dispersed in an aqueous subphase onto a monolayer of the phospholipid dipalmitoyl-l-α-phosphatidylcholine (DPPC) at the air-water interface. It has been used to prepare patterns of nanoparticles of Prussian blue analogues (PBA) of different size (K(0.25)Ni[Fe(CN)(6)](0.75) (NiFe), K(0.25)Ni[Cr(CN)(6)](0.75) (NiCr), K(0.25)Ni[Co(CN)(6)](0.75) (NiCo), Cs(0.4)Co[Cr(CN)(6)](0.8) (CsCoCr), and Cs(0.4)Co[Fe(CN)(6)](0.9) (CsCoFe)). The behavior of DPPC monolayer at the air-water interface in the presence of the subphase of P…

Langmuir-Blodgett films based on Prussian Blue derivatives: Towards new hybrid magnetic materials

1999

Abstract The adsorption of dissolved Prussian Blue derivatives along a positively charged monolayer leads to new Langmuir-Blodgett (LB) films presenting a ferromagnetic state at low temperature. Such organic/inorganic systems containing inorganic sheets between organic amphiphilic layers constitute a new series of magnetic lamellar materials.

Baltu filoloģija, 30, sēj., Nr. 1/2

2021

Informācijas tehnoloģijas terminu lietošanas paradumi publiskajā saziņā

2013

Informācijas un komunikācijas tehnoloģijas (IKT) termini galvenokārt tiek radīti angļu valodā un pēc tam lokalizēti citās valodās. Valodu morfoloģisko un terminrades tradīciju atšķirību dēļ šāda lokalizācija mēdz būt diezgan haotiska. Latvijas IKT terminu lokalizētāji ir izstrādājuši samērā stingru, t.s. kvazialgoritmisko pieeju, ko aprobējuši vairāk nekā 15 gadu laikā. Šajā rakstā uz biežāk lietoto terminu piemēra parādīta pieejas dzīvotspēja. Noraidīts izplatītais uzskats, ka IKT terminu lokalizējumi piesārņo latviešu valodu ar svešvārdiem. Analizēta oficiāli apstiprināto terminu lietojamība tekstos un iemesli, kādēļ tie dažkārt sastop ikdienas lietotāju pretestību.

P294 Benefits of tiotropium/olodaterol over tiotropium at delaying clinically significant events in patients with copd classified as gold B

2016

Rationale The once-daily combination of tiotropium (T), a long-acting muscarinic antagonist, and olodaterol (O), a long-acting β 2 -agonist, has demonstrated efficacy and safety in COPD. Two large clinical studies (TONADO ® 1 + 2) have also demonstrated the benefits of T/O compared to the monocomponents in patients with moderate to very severe COPD. This post hoc analysis investigated whether T/O is more effective than T at delaying clinically significant events in patients with GOLD stage B COPD. Methods A total of 5162 patients were randomised to O 5 µg, T 2.5 µg, T 5 µg, T/O 2.5/5 µg or T/O 5/5 µg (delivered via Respimat ® inhaler) in two 52-week, parallel-group, double-blind studies (NC…

Benefits of Tiotropium + Olodaterol Over Tiotropium at Delaying Clinically Significant Events in Patients with COPD Classified as GOLD B

2017

Lung Deposition Using the Respimat® Soft Mist™ Inhaler Mono and Fixed-Dose Combination Therapies: An In Vitro/In Silico Analysis

2020

Tiotropium and olodaterol are mainstay treatments for chronic obstructive pulmonary disease (COPD) and yield important clinical improvements, especially when used in fixed-dose combination. Whilst previous studies have shown consistent delivery of tiotropium to the lungs with the Respimat® inhaler, no such study has been carried out for olodaterol or the components of their fixed-dose combination (TIO/OLO). Combining in vitro and in silico models, we measured the amount of drug retained in the mouth–throat area, entering the trachea and reaching the lung periphery. We applied a hybrid deposition model that considered the experimentally determined output of an Alberta throat model (in vitro …

β-Blockers in COPD

2018

Background Cardiovascular disease is a frequent comorbidity in patients with COPD. Many physicians, particularly pulmonologists, are reluctant to use β-adrenoceptor blocking agents (β-blockers) in patients with COPD, despite their proven effectiveness in preventing cardiovascular events. Methods The large (5,162 patients) phase III TONADO 1 and 2 studies assessed lung function and patient-reported outcomes in patients with moderate to very severe COPD receiving long-acting bronchodilator treatment across 1 year. This post hoc analysis characterized lung-function changes, patient-reported outcomes, and safety in the subgroup of patients receiving β-blockers in the studies. Results In total, …

Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials.

2018

Abstract Background An extensive clinical trial program supports the efficacy and safety of tiotropium/olodaterol in chronic obstructive pulmonary disease (COPD). We examined the safety of tiotropium/olodaterol compared with tiotropium in a large population of patients, focusing on cardiovascular and respiratory events. Methods Patients (n = 9942) who received once-daily tiotropium/olodaterol 5/5 μg or tiotropium 5 μg (via Respimat®) in TONADO 1 & 2 and DYNAGITO were included. The number of patients and exposure-adjusted rate of events are presented for adverse events (AEs), serious AEs (SAEs), AEs leading to discontinuation, and cardiovascular and respiratory events. Findings Fewer patient…